<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="pmcid: 7334951S1359-6101(20)30164-7 doi: 10.1016/j.cytogfr.2020.07.010 : Article Are we fully exploiting" exact="type I" post="Interferons in today's fight against COVID-19 pandemic? AricÃ²Eleonoraa1BracciLaurab1CastielloLucianoaGessaniSandracBelardelliFilippod*[a], [b],"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="in particular IFN-Î², are promising drugs for SARS-CoV2 infection. â€¢Early" exact="infection" post="in elderly patients is the best setting to exploit"/>
 <result pre="to IFN-I treatment in patients with severe COVID-19. Abstract Coronavirus" exact="disease" post="2019 (COVID-19) first emerged in late 2019 in China."/>
 <result pre="million individuals and causing more than 460,000 deaths. In the" exact="absence of" post="vaccines, we are facing the dramatic challenge of controlling"/>
 <result pre="dramatic challenge of controlling COVID-19 pandemic. Among currently available drugs," exact="type I" post="Interferons (IFN-I) â€&quot; mainly IFN-Î± and Î² â€&quot;represent ideal"/>
 <result pre="dosing, timing and route of administration of IFN-I to the" exact="disease" post="stage, with the final aim of making these cytokines"/>
 <result pre="valuable therapeutic strategy in today's fight against COVID-19 pandemic. Keywords" exact="Type I" post="Interferons COVID-19 SARS-CoV-2 Coronavirus Mucosal treatments Immunomodulation Antiviral therapy"/>
 <result pre="against COVID-19 pandemic. Keywords Type I Interferons COVID-19 SARS-CoV-2 Coronavirus" exact="Mucosal" post="treatments Immunomodulation Antiviral therapy Antiviral Immune Response Beta Interferon"/>
 <result pre="Interferon 1 Introduction The rapid and devastating outbreak of Coronavirus" exact="disease" post="2019 (COVID-19) pandemic and the lack of approved treatments"/>
 <result pre="the lack of approved treatments for any human coronavirus (CoV)" exact="infection" post="highlight the urgent need to develop strategies to prevent"/>
 <result pre="to develop strategies to prevent infection, control virus spreading and" exact="disease" post="exacerbation. Several options can be envisaged, ranging from prophylactic"/>
 <result pre="or drug combinations capable of attenuating the virulence of the" exact="disease" post="[2]. Some of these trials include the use of"/>
 <result pre="immune responses, with an important role in the inhibition of" exact="viral" post="replication, through different receptor molecules and effector proteins [3]."/>
 <result pre="and effector proteins [3]. There are three types of IFN," exact="Type I" post="(IFN-Î±/Î²), Type II (IFN-Î³), and Type III (IFN-Î»). Although"/>
 <result pre="[3]. There are three types of IFN, Type I (IFN-Î±/Î²)," exact="Type II" post="(IFN-Î³), and Type III (IFN-Î»). Although all three are"/>
 <result pre="types of IFN, Type I (IFN-Î±/Î²), Type II (IFN-Î³), and" exact="Type III" post="(IFN-Î»). Although all three are likely involved in protection"/>
 <result pre="all three are likely involved in protection against CoV infection," exact="Type I" post="IFN (IFN-I) and IFN-Î» are the most studied in"/>
 <result pre="substances produced by influenza virus-infected cells, capable of markedly inhibiting" exact="viral" post="replication in target cells [9]. These cytokines were the"/>
 <result pre="cloned and have been extensively used in patients with some" exact="viral" post="diseases [10] and cancer (IFN-Î±) [11], and in the"/>
 <result pre="extensively used in patients with some viral diseases [10] and" exact="cancer" post="(IFN-Î±) [11], and in the treatment of relapsing-remitting multiple"/>
 <result pre="[10] and cancer (IFN-Î±) [11], and in the treatment of" exact="relapsing-remitting multiple sclerosis" post="(MS) (IFN-Î², [12]). Indeed, IFN-I are pleiotropic factors endowed"/>
 <result pre="and cancer (IFN-Î±) [11], and in the treatment of relapsing-remitting" exact="multiple sclerosis" post="(MS) (IFN-Î², [12]). Indeed, IFN-I are pleiotropic factors endowed"/>
 <result pre="of IFN-I has been extensively exploited for the treatment of" exact="viral" post="chronic infections [10]. Nevertheless, as highlighted by the long"/>
 <result pre="IFN-I has been extensively exploited for the treatment of viral" exact="chronic" post="infections [10]. Nevertheless, as highlighted by the long clinical"/>
 <result pre="has been extensively exploited for the treatment of viral chronic" exact="infections" post="[10]. Nevertheless, as highlighted by the long clinical records"/>
 <result pre="the IFN-I system and the dysregulated IFN-I response in SARS-CoV-2" exact="infection" post="point to the need of a fine-tuning of route,"/>
 <result pre="SARS-CoV-2: one virus, multiple battlefronts Differently from the 2002 severe" exact="acute" post="respiratory syndrome (SARS)-CoV, SARS-CoV-2 has a lower virulence with"/>
 <result pre="one virus, multiple battlefronts Differently from the 2002 severe acute" exact="respiratory" post="syndrome (SARS)-CoV, SARS-CoV-2 has a lower virulence with a"/>
 <result pre="virus, multiple battlefronts Differently from the 2002 severe acute respiratory" exact="syndrome" post="(SARS)-CoV, SARS-CoV-2 has a lower virulence with a large"/>
 <result pre="the 2002 severe acute respiratory syndrome (SARS)-CoV, SARS-CoV-2 has a" exact="lower" post="virulence with a large number of asymptomatic infections and"/>
 <result pre="has a lower virulence with a large number of asymptomatic" exact="infections" post="and mild upper respiratory tract illness [14,15]. This is"/>
 <result pre="virulence with a large number of asymptomatic infections and mild" exact="upper" post="respiratory tract illness [14,15]. This is a determinant factor"/>
 <result pre="with a large number of asymptomatic infections and mild upper" exact="respiratory" post="tract illness [14,15]. This is a determinant factor for"/>
 <result pre="transmissibility, considering that asymptomatic or presymptomatic carriers might contribute to" exact="viral" post="transmission, especially in high-risk populations [16]. Even though upper"/>
 <result pre="to viral transmission, especially in high-risk populations [16]. Even though" exact="upper" post="respiratory infections are often spontaneously resolved, some of these"/>
 <result pre="viral transmission, especially in high-risk populations [16]. Even though upper" exact="respiratory" post="infections are often spontaneously resolved, some of these eventually"/>
 <result pre="transmission, especially in high-risk populations [16]. Even though upper respiratory" exact="infections" post="are often spontaneously resolved, some of these eventually progress"/>
 <result pre="spontaneously resolved, some of these eventually progress in more severe" exact="viral pneumonia." post="Severe COVID-19 patients are characterized by a strong immune"/>
 <result pre="some of these eventually progress in more severe viral pneumonia." exact="Severe" post="COVID-19 patients are characterized by a strong immune activation"/>
 <result pre="lung infiltration by proinflammatory macrophages and granulocytes [18], development of" exact="acute" post="respiratory distress syndrome, respiratory failure and subsequent fatality (Fig."/>
 <result pre="infiltration by proinflammatory macrophages and granulocytes [18], development of acute" exact="respiratory" post="distress syndrome, respiratory failure and subsequent fatality (Fig. 1"/>
 <result pre="macrophages and granulocytes [18], development of acute respiratory distress syndrome," exact="respiratory" post="failure and subsequent fatality (Fig. 1 ). Age, sex"/>
 <result pre="Ageing is indeed characterized by the gradual development of a" exact="chronic" post="subclinical systemic inï¬‚ammation and by acquired immune impairment, particularly"/>
 <result pre="indeed characterized by the gradual development of a chronic subclinical" exact="systemic" post="inï¬‚ammation and by acquired immune impairment, particularly in the"/>
 <result pre="gradual development of a chronic subclinical systemic inï¬‚ammation and by" exact="acquired" post="immune impairment, particularly in the male population [21]. In"/>
 <result pre="particular, recent studies have shown that ageing affects B lymphocyte-driven" exact="acquired" post="immunity [22], attenuates the upregulation of co-stimulatory molecules for"/>
 <result pre="and reduces IFN-I production by alveolar phagocytes in response to" exact="viral infection" post="[19]. Fig. 1 COVID-19 and IFN-I treatment. In the"/>
 <result pre="reduces IFN-I production by alveolar phagocytes in response to viral" exact="infection" post="[19]. Fig. 1 COVID-19 and IFN-I treatment. In the"/>
 <result pre="treatment. In the majority of patients (left panels) early phase" exact="infection" post="results in a physiological IFN-I activation that favors the"/>
 <result pre="effect. This immune activation leads to a resolution of the" exact="infection" post="without any need of treatment. Instead, approximately 15â€&quot;20 %"/>
 <result pre="early IFN-I activation show a dysfunctional immune response with higher" exact="viral" post="spread. This situation is then followed by an excessive"/>
 <result pre="benefit of an IFN-I treatment at the early phase of" exact="infection" post="(right panels) as it would re-establish a functional immune"/>
 <result pre="infection. At bottom, diagrams summarizing the variation over time of" exact="infection" post="levels and immune response for each scenario. This figure"/>
 <result pre="mechanisms intervening in early stage versus late stage of SARS-CoV-2" exact="infection" post="(reviewed in [17]) and to the role of comorbidities"/>
 <result pre="(reviewed in [17]) and to the role of comorbidities in" exact="disease" post="exacerbation, interventions should be carefully tailored to the stage"/>
 <result pre="interventions should be carefully tailored to the stage of the" exact="disease" post="and to the target population with the aim of"/>
 <result pre="and MERS-CoV, as well as the immunologic changes observed during" exact="infection" post="[23] point to a dysregulated IFN-I response in COVID-19"/>
 <result pre="point to a dysregulated IFN-I response in COVID-19 pathogenesis and" exact="disease" post="outcome [24]. Diminished levels of IFN-I were already detected"/>
 <result pre="revealed no expression of IFN-I or IFN-stimulated genes (ISG) in" exact="peripheral" post="blood mononuclear cells, suggesting a viral-induced inhibition of their"/>
 <result pre="(RIG-I, MDA5 and IRF3/7) was associated with the severity of" exact="disease" post="and fatal outcomes in MERS patients [26]. Likewise, SARS-CoV-2"/>
 <result pre="disease and fatal outcomes in MERS patients [26]. Likewise, SARS-CoV-2" exact="infection" post="(either in cell lines, primary cell cultures, ferrets, and"/>
 <result pre="MERS patients [26]. Likewise, SARS-CoV-2 infection (either in cell lines," exact="primary" post="cell cultures, ferrets, and COVID-19 patients) drives a lower"/>
 <result pre="lines, primary cell cultures, ferrets, and COVID-19 patients) drives a" exact="lower" post="antiviral transcriptional response that is marked by low IFN-I"/>
 <result pre="levels and elevated chemokine expression, which could explain the proinflammatory" exact="disease" post="state associated with COVID-19. In patients with severe COVID-19,"/>
 <result pre="severe COVID-19, an impaired IFN-I signalling associated with persistent blood" exact="viral" post="load and an exacerbated inflammatory response was recently reported"/>
 <result pre="unit stay [28]. Other studies suggest that rather than a" exact="complete" post="absence, the IFN response may be delayed. Compelling evidence"/>
 <result pre="response may be delayed. Compelling evidence indicated that human bronchial" exact="epithelial" post="cells are capable of promoting active, but delayed IFN-related"/>
 <result pre="active, but delayed IFN-related antiviral responses to SARS-CoV and MERS-CoV" exact="infection" post="[29,30]. These results are in line with data on"/>
 <result pre="data on mouse model of SARS-CoV infection, where a robust" exact="viral" post="replication associated with delayed IFN-I signaling was reported to"/>
 <result pre="responses, leading to accumulation of pathogenic monocytes-macrophages promoting lung immunopathology," exact="vascular" post="leakage and suboptimal T cell response with decreased survival"/>
 <result pre="exogenous administration of IFN-Î² completely protected mice from lethal MERS-CoV" exact="infection" post="by inhibiting virus replication and inflammatory cytokine production, delayed"/>
 <result pre="in IFN-I, ISG, and inflammatory cytokine levels, resulting in fatal" exact="disease" post="[32]. In conclusion, in comparison to other respiratory viruses,"/>
 <result pre="in fatal disease [32]. In conclusion, in comparison to other" exact="respiratory" post="viruses, SARS-CoV-2 infection drives a lower antiviral transcriptional response"/>
 <result pre="[32]. In conclusion, in comparison to other respiratory viruses, SARS-CoV-2" exact="infection" post="drives a lower antiviral transcriptional response that is marked"/>
 <result pre="in comparison to other respiratory viruses, SARS-CoV-2 infection drives a" exact="lower" post="antiviral transcriptional response that is marked by low IFN-I"/>
 <result pre="levels and elevated chemokine expression, which could explain the proinflammatory" exact="disease" post="state associated with COVID-19 [33]. Overall, these observations outline"/>
 <result pre="conditions, IFN-I are produced at low levels. However, upon RNA" exact="viral" post="recognition through the endosomal (i.e. Toll-like receptors) or cytosolic"/>
 <result pre="RNA viral recognition through the endosomal (i.e. Toll-like receptors) or" exact="cytosolic" post="(RIG-I-like receptors) pattern recognition receptors, the activation of downstream"/>
 <result pre="In the early phases of infection, IFN-I contribute to limit" exact="viral" post="spread by activating NK cells [35] and enhancing their"/>
 <result pre="DC exposed to IFN-I show a peculiar ability to cross-present" exact="viral" post="antigens to naÃ¯ve CD8+ T cells [36], promote Th1"/>
 <result pre="of NK, T and B cells at the site of" exact="infection" post="[38]. Notably, the interplay IFN-I/DC is crucial for the"/>
 <result pre="crucial for the generation of protective antibodies against reference and" exact="viral" post="antigens [[39], [40], [41], [42]]. In fact, the stimulation"/>
 <result pre="or by IFN inducers, such as poly(I:C), strongly enhance the" exact="primary" post="antibody response (especially IgG2a) to reference antigens [39] or"/>
 <result pre="standard influenza vaccine [42] in mice. Interestingly, even in the" exact="absence of" post="a direct antiviral effect, the continuous production of IFN-Î±"/>
 <result pre="a significant antiviral immune response attenuating the severity of the" exact="infection" post="and protecting against subsequent viral challenge [43]. This evidence"/>
 <result pre="attenuating the severity of the infection and protecting against subsequent" exact="viral" post="challenge [43]. This evidence supports the concept that IFN-I,"/>
 <result pre="supports the concept that IFN-I, rapidly produced in response to" exact="viral infection," post="stimulate the generation of a protective humoral immunity. Based"/>
 <result pre="were used in pilot studies as a vaccine adjuvant in" exact="infective" post="diseases [44]. IFN-Î± local injection in close proximity of"/>
 <result pre="the HBV vaccine showed evidence of clinical efficacy in the" exact="absence of" post="any toxicity [44]. Overall, although our knowledge of the"/>
 <result pre="can represent not only a direct antiviral treatment restricting early" exact="viral" post="spread, but also a valuable tool to enhance humoral"/>
 <result pre="valuable tool to enhance humoral and cellular immunity, thus halting" exact="viral infection" post="from progressing towards a more severe form of disease."/>
 <result pre="tool to enhance humoral and cellular immunity, thus halting viral" exact="infection" post="from progressing towards a more severe form of disease."/>
 <result pre="a matter of timing? The past experience on IFN-I in" exact="cancer" post="and chronic viral infection was mainly based on repeated"/>
 <result pre="of timing? The past experience on IFN-I in cancer and" exact="chronic" post="viral infection was mainly based on repeated intravenous (i.v.)"/>
 <result pre="timing? The past experience on IFN-I in cancer and chronic" exact="viral infection" post="was mainly based on repeated intravenous (i.v.) or subcutaneous"/>
 <result pre="The past experience on IFN-I in cancer and chronic viral" exact="infection" post="was mainly based on repeated intravenous (i.v.) or subcutaneous"/>
 <result pre="monotherapy or in combination, but the rate of success was" exact="limited" post="[51]. In some cases, in line with data emerging"/>
 <result pre="response (Fig. 1). Besides being less effective if given when" exact="viral" post="replication is reaching its peak, attention should be paid"/>
 <result pre="possible adverse effects of IFN-I administration when SARS-CoV-2 cytokine release" exact="syndrome" post="is already ongoing. It is clear that cytokine accumulation"/>
 <result pre="plasma of severe COVID-19 patients is not the result of" exact="systemic" post="immune activation, but it is rather caused by virus-mediated"/>
 <result pre="rather caused by virus-mediated stimulation of alveolar macrophages and lung" exact="epithelial" post="cells [52]. Nevertheless, we cannot exclude that the immunomodulation"/>
 <result pre="exclude that the immunomodulation phenomena occurring upon IFN-Î± or Î²" exact="systemic" post="treatment may concur in the stimulation of pro-inflammatory cytokines"/>
 <result pre="safe and effective use of IFN-Î± or Î² administration is" exact="limited" post="to the first 10 days since the SARS-CoV-2 diagnosis."/>
 <result pre="the treatment of severe COVID-19 patients should be discouraged. 6" exact="Mucosal" post="delivery of IFN-I: is this strategy ready for efficiently"/>
 <result pre="this strategy ready for efficiently fighting COVID-19 pandemic? Since the" exact="respiratory" post="mucosa is the primary portal of entry for SARS-CoV-2,"/>
 <result pre="strategy ready for efficiently fighting COVID-19 pandemic? Since the respiratory" exact="mucosa" post="is the primary portal of entry for SARS-CoV-2, there"/>
 <result pre="efficiently fighting COVID-19 pandemic? Since the respiratory mucosa is the" exact="primary" post="portal of entry for SARS-CoV-2, there is increasing interest"/>
 <result pre="COVID-19. The first attempts to deliver IFN-I to the nasal" exact="mucosa" post="to counteract respiratory infections date back in the 1970s"/>
 <result pre="attempts to deliver IFN-I to the nasal mucosa to counteract" exact="respiratory" post="infections date back in the 1970s [54]. Since then,"/>
 <result pre="to deliver IFN-I to the nasal mucosa to counteract respiratory" exact="infections" post="date back in the 1970s [54]. Since then, intranasal"/>
 <result pre="of IFN-I has been repeatedly explored as prophylactic measure against" exact="respiratory" post="infections with variable results that mostly depended on the"/>
 <result pre="IFN-I has been repeatedly explored as prophylactic measure against respiratory" exact="infections" post="with variable results that mostly depended on the dose"/>
 <result pre="that the intranasal route may unwantedly deliver compounds to the" exact="central nervous system," post="thus causing toxicity [58]. Among mucosal routes, sublingual administration"/>
 <result pre="dosage IFN-Î± preparation proved safe and effective as prophylaxis against" exact="respiratory" post="viral infections [59]. The data available thus far suggest"/>
 <result pre="IFN-Î± preparation proved safe and effective as prophylaxis against respiratory" exact="viral" post="infections [59]. The data available thus far suggest that"/>
 <result pre="preparation proved safe and effective as prophylaxis against respiratory viral" exact="infections" post="[59]. The data available thus far suggest that the"/>
 <result pre="perform, while retaining the capability of inducing both local and" exact="systemic" post="effects potentially protective in the very early phases of"/>
 <result pre="administration of IFN-Î± to medical staff at risk of SARS-CoV-2" exact="infection" post="results in complete protection [61]. Since the beneficial effects"/>
 <result pre="to medical staff at risk of SARS-CoV-2 infection results in" exact="complete" post="protection [61]. Since the beneficial effects of mucosal IFN-I"/>
 <result pre="further studies are needed to confirm IFN-I efficacy against SARS-CoV-2" exact="infection" post="and to better characterize the biological activities, the mechanisms"/>
 <result pre="Delivery route ChiCTR2000029638 Recruiting Supercompound Alone 18âˆ’75 mucosal ChiCTR2000030117 Recruiting" exact="Alpha" post="Combination (antivirals) 18âˆ’70 ChiCTR2000030013 Not Recruiting Alpha Alone n.a.â€¡"/>
 <result pre="mucosal ChiCTR2000030117 Recruiting Alpha Combination (antivirals) 18âˆ’70 ChiCTR2000030013 Not Recruiting" exact="Alpha" post="Alone n.a.â€¡ NCT04254874 Recruiting Peg-Alpha-2b Combination (antivirals) &amp;gt;18 NCT04349410"/>
 <result pre="Combination (antivirals) &amp;gt;18 NCT04349410 Recruiting Alpha-2b Alone all ChiCTR2000029600 Recruiting" exact="Alpha" post="Alone &amp;amp; in combination 16âˆ’75 ChiCTR2000029756 Recruiting Alpha Alone"/>
 <result pre="ChiCTR2000029600 Recruiting Alpha Alone &amp;amp; in combination 16âˆ’75 ChiCTR2000029756 Recruiting" exact="Alpha" post="Alone 18âˆ’60 ChiCTR2000031196 Recruiting Alpha Combination (antivirals) 16âˆ’85 NCT04293887"/>
 <result pre="in combination 16âˆ’75 ChiCTR2000029756 Recruiting Alpha Alone 18âˆ’60 ChiCTR2000031196 Recruiting" exact="Alpha" post="Combination (antivirals) 16âˆ’85 NCT04293887 Not recruiting Alpha-1b Combination (standard"/>
 <result pre="NCT04320238 Recruiting Alpha-1b Alone &amp;amp; in combination 18âˆ’65 ChiCTR2000030535 Recruiting" exact="Alpha" post="Combination (antivirals) n.a. NCT04251871 Recruiting Alpha Combination (antiviralsâ€¯+â€¯traditional chinese"/>
 <result pre="combination 18âˆ’65 ChiCTR2000030535 Recruiting Alpha Combination (antivirals) n.a. NCT04251871 Recruiting" exact="Alpha" post="Combination (antiviralsâ€¯+â€¯traditional chinese medicine) 14âˆ’80 ChiCTR2000030480 Recruiting Alpha-1b Alone"/>
 <result pre="medicine) 14âˆ’80 ChiCTR2000030480 Recruiting Alpha-1b Alone 18âˆ’110 NCT04275388 Not recruiting" exact="Alpha" post="Combination (antivirals) &amp;lt;100 ChiCTR2000029989 Not Recruiting Alpha-1b Alone &amp;gt;60"/>
 <result pre="(antivirals) &amp;lt;100 ChiCTR2000029989 Not Recruiting Alpha-1b Alone &amp;gt;60 NCT04273763 Recruiting" exact="Alpha" post="Combination (antivirals) 18âˆ’80 ChiCTR2000030166 Not Recruiting Alpha Combination (antivirals)"/>
 <result pre="&amp;gt;60 NCT04273763 Recruiting Alpha Combination (antivirals) 18âˆ’80 ChiCTR2000030166 Not Recruiting" exact="Alpha" post="Combination (antivirals) n.a. systemic NCT04379518 Not recruiting Alpha-2b Combination"/>
 <result pre="Combination (antivirals) 18âˆ’80 ChiCTR2000030166 Not Recruiting Alpha Combination (antivirals) n.a." exact="systemic" post="NCT04379518 Not recruiting Alpha-2b Combination (Rintatolimod) &amp;gt;18 RPCEC00000307 Recruiting"/>
 <result pre="Recruiting Long acting Alpha-2a Combination (antivirals) 18âˆ’65 n.a. ChiCTR2000029387 Recruiting" exact="Alpha" post="Combination (antivirals) 18âˆ’65 n.a. IRCT20200511047396N1 Recruiting Beta-1a Alone &amp;gt;18"/>
 <result pre="Beta Combination (antivirals) n.a. ISRCTN83971151 Recruiting Beta Combination (antivirals) n.a." exact="systemic" post="IRCT20151227025726N12 Recruiting Beta Combination (antivirals) &amp;gt;18 IRCT20100228003449N28 Recruiting Beta"/>
 <result pre="a mucosal delivery of IFN-I, besides being targeted at the" exact="infection" post="site, could be more compliant and less toxic than"/>
 <result pre="administration, especially for prophylaxis in subjects at high risk of" exact="infection" post="or in early phases of household management of infected"/>
 <result pre="pharmacokinetics of mucosal IFN-I preparation, thus defining the risks of" exact="central nervous system" post="toxicity [especially when IFN-Î² is used [63] and achieving"/>
 <result pre="routes, their mechanisms of action and toxicity limitations. A continuous" exact="systemic" post="treatment, somehow inspired by the conventional use of these"/>
 <result pre="by the conventional use of these cytokines in patients with" exact="chronic hepatitis C" post="infection and cancer, has been suggested in some of"/>
 <result pre="the conventional use of these cytokines in patients with chronic" exact="hepatitis C" post="infection and cancer, has been suggested in some of"/>
 <result pre="use of these cytokines in patients with chronic hepatitis C" exact="infection" post="and cancer, has been suggested in some of the"/>
 <result pre="investigators observed significant symptoms alleviation, shortening of the duration of" exact="viral" post="shedding and of hospital stay only in IFN-treated patients"/>
 <result pre="with mild to moderate COVID-19 [64]. Notably, due to the" exact="absence of" post="single treatment arms in this clinical study, it cannot"/>
 <result pre="least in part, responsible for the spontaneous resolution of SARS-CoV-2" exact="infection" post="in the majority of infected patients (estimated around 80"/>
 <result pre="may represent determinants of IFN impairment and important cofactors in" exact="disease" post="outcome [[19], [20], [21]], could greatly benefit from a"/>
 <result pre="[[19], [20], [21]], could greatly benefit from a time-limited, intermittent," exact="systemic" post="(s.c. or i.m.) IFN-I administration (2â€&quot;4 million per injection)"/>
 <result pre="understand the role of the endogenous IFN-I signaling in the" exact="susceptibility to" post="SARS-CoV-2 infection and in the progression to the severe"/>
 <result pre="of the endogenous IFN-I signaling in the susceptibility to SARS-CoV-2" exact="infection" post="and in the progression to the severe forms of"/>
 <result pre="COVID-19, in order to identify markers of resistance to the" exact="disease" post="and tailor IFN treatments to the patients with the"/>
 <result pre="treatment schedules should be used in the early stages of" exact="infection" post="to compensate for virus-induced IFN-impairment or IFN-deficiency in the"/>
 <result pre="COVID-19Cell Host Microbe27202087087810.1016/j.chom.2020.05.00832464097 5SchreiberG.PiehlerJ.The molecular basis for functional plasticity in" exact="type I" post="interferon signalingTrends Immunol.36201513914910.1016/j.it.2015.01.00225687684 6LokugamageK.G.HageA.SchindewolfC.RajsbaumR.MenacheryV.D.SARS-CoV-2 is Sensitive To Type I"/>
 <result pre="in type I interferon signalingTrends Immunol.36201513914910.1016/j.it.2015.01.00225687684 6LokugamageK.G.HageA.SchindewolfC.RajsbaumR.MenacheryV.D.SARS-CoV-2 is Sensitive To" exact="Type I" post="Interferon Pretreatment2020Cold Spring Harbor Laboratory10.1101/2020.03.07.982264 7HensleyL.E.FritzE.A.JahrlingP.B.KarpC.L.HugginsJ.W.GeisbertT.W.Interferon-Î² 1a and SARS"/>
 <result pre="Dis.10200431731910.3201/eid1002.03048215030704 8ScagnolariC.VicenziE.BellomiF.StillitanoM.G.PinnaD.PoliG.ClementiM.DianzaniF.AntonelliG.Increased sensitivity of SARS-coronavirus to a combination of human" exact="type I" post="and type II interferonsAntivir. Ther. (Lond.)920041003101115651759 9VilcekJ.Fifty years of"/>
 <result pre="of SARS-coronavirus to a combination of human type I and" exact="type II" post="interferonsAntivir. Ther. (Lond.)920041003101115651759 9VilcekJ.Fifty years of interferon research: aiming"/>
 <result pre="interferon-based therapies for multiple sclerosisExpert Opin. Biol. Ther.18201866568010.1080/14712598.2018.146279329624084 13RizzaP.MorettiF.CaponeI.BelardelliF.Role of" exact="type I" post="interferon in inducing a protective immune response: perspectives for"/>
 <result pre="for clinical applicationsCytokine Growth Factor Rev.26201519520110.1016/j.cytogfr.2014.10.00225466627 14FungS.-Y.YuenK.-S.YeZ.-W.ChanC.-P.JinD.-Y.A tug-of-war between severe" exact="acute" post="respiratory syndrome coronavirus 2 and host antiviral defence: lessons"/>
 <result pre="clinical applicationsCytokine Growth Factor Rev.26201519520110.1016/j.cytogfr.2014.10.00225466627 14FungS.-Y.YuenK.-S.YeZ.-W.ChanC.-P.JinD.-Y.A tug-of-war between severe acute" exact="respiratory" post="syndrome coronavirus 2 and host antiviral defence: lessons from"/>
 <result pre="applicationsCytokine Growth Factor Rev.26201519520110.1016/j.cytogfr.2014.10.00225466627 14FungS.-Y.YuenK.-S.YeZ.-W.ChanC.-P.JinD.-Y.A tug-of-war between severe acute respiratory" exact="syndrome" post="coronavirus 2 and host antiviral defence: lessons from other"/>
 <result pre="antiviral defence: lessons from other pathogenic virusesEmerg. Microbes Infect.9202055857010.1080/22221751.2020.173664432172672 15ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.GuoQ.SongT.HeJ.YenH.-L.PeirisM.WuJ.SARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patientsN. Engl."/>
 <result pre="from other pathogenic virusesEmerg. Microbes Infect.9202055857010.1080/22221751.2020.173664432172672 15ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.GuoQ.SongT.HeJ.YenH.-L.PeirisM.WuJ.SARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patientsN. Engl. J. Med.38220201177117910.1056/NEJMc200173732074444 16AronsM.M.HatfieldK.M.ReddyS.C.KimballA.JamesA.JacobsJ.R.TaylorJ.SpicerK.BardossyA.C.OakleyL.P.TanwarS.DyalJ.W.HarneyJ.ChistyZ.BellJ.M.MethnerM.PaulP.CarlsonC.M.McLaughlinH.P.ThornburgN.TongS.TaminA.TaoY.UeharaA.HarcourtJ.ClarkS.Brostrom-SmithC.PageL.C.KayM.LewisJ.MontgomeryP.StoneN.D.ClarkT.A.HoneinM.A.DuchinJ.S.JerniganJ.A.Presymptomatic"/>
 <result pre="other pathogenic virusesEmerg. Microbes Infect.9202055857010.1080/22221751.2020.173664432172672 15ZouL.RuanF.HuangM.LiangL.HuangH.HongZ.YuJ.KangM.SongY.XiaJ.GuoQ.SongT.HeJ.YenH.-L.PeirisM.WuJ.SARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patientsN. Engl. J. Med.38220201177117910.1056/NEJMc200173732074444 16AronsM.M.HatfieldK.M.ReddyS.C.KimballA.JamesA.JacobsJ.R.TaylorJ.SpicerK.BardossyA.C.OakleyL.P.TanwarS.DyalJ.W.HarneyJ.ChistyZ.BellJ.M.MethnerM.PaulP.CarlsonC.M.McLaughlinH.P.ThornburgN.TongS.TaminA.TaoY.UeharaA.HarcourtJ.ClarkS.Brostrom-SmithC.PageL.C.KayM.LewisJ.MontgomeryP.StoneN.D.ClarkT.A.HoneinM.A.DuchinJ.S.JerniganJ.A.Presymptomatic SARS-CoV-2"/>
 <result pre="respiratory specimens of infected patientsN. Engl. J. Med.38220201177117910.1056/NEJMc200173732074444 16AronsM.M.HatfieldK.M.ReddyS.C.KimballA.JamesA.JacobsJ.R.TaylorJ.SpicerK.BardossyA.C.OakleyL.P.TanwarS.DyalJ.W.HarneyJ.ChistyZ.BellJ.M.MethnerM.PaulP.CarlsonC.M.McLaughlinH.P.ThornburgN.TongS.TaminA.TaoY.UeharaA.HarcourtJ.ClarkS.Brostrom-SmithC.PageL.C.KayM.LewisJ.MontgomeryP.StoneN.D.ClarkT.A.HoneinM.A.DuchinJ.S.JerniganJ.A.Presymptomatic SARS-CoV-2" exact="infections" post="and transmission in a skilled nursing facilityN. Engl. J."/>
 <result pre="COVID-19: current state of the scienceImmunity.202010.1016/j.immuni.2020.05.002 18YuS.-Y.Gene expression profiles in" exact="peripheral" post="blood mononuclear cells of SARS patientsWorld J. Gastroenterol.112005503710.3748/wjg.v11.i32.503716124062 19ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.GuanL.WeiY.LiH.WuX.XuJ.TuS.ZhangY.ChenH.CaoB.Clinical"/>
 <result pre="J. Gastroenterol.112005503710.3748/wjg.v11.i32.503716124062 19ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.GuanL.WeiY.LiH.WuX.XuJ.TuS.ZhangY.ChenH.CaoB.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="20ContiP.YounesA.Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to" exact="viral" post="infectionJ. Biol. Regul. Homeost. Agents34202010.23812/Editorial-Conti-3 21BonafÃ¨M.PrattichizzoF.GiulianiA.StorciG.SabbatinelliJ.OlivieriF.Inflamm-Aging: Why Older Men"/>
 <result pre="21BonafÃ¨M.PrattichizzoF.GiulianiA.StorciG.SabbatinelliJ.OlivieriF.Inflamm-Aging: Why Older Men Are the Most Susceptible to SARS-Cov-2" exact="Complicated" post="Outcomes202011710.20944/PREPRINTS202004.0143.V1 22MÃ¡rquezE.J.han ChungC.MarchesR.RossiR.J.Nehar-BelaidD.ErogluA.MellertD.J.KuchelG.A.BanchereauJ.UcarD.Sexual-dimorphism in human immune system agingNat. Commun.11202011710.1038/s41467-020-14396-931911652"/>
 <result pre="patients with COVID-19 in Wuhan, ChinaClin. Infect. Dis.202010.1093/cid/ciaa248 24AcharyaD.LiuG.GackM.U.Dysregulation of" exact="type I" post="interferon responses in COVID-19Nat. Rev. Immunol.20201210.1038/s41577-020-0346-x31792373 25ReghunathanR.JayapalM.HsuL.Y.ChngH.H.TaiD.LeungB.P.MelendezA.J.Expression profile of"/>
 <result pre="25ReghunathanR.JayapalM.HsuL.Y.ChngH.H.TaiD.LeungB.P.MelendezA.J.Expression profile of immune response genes in patients with severe" exact="acute" post="respiratory syndromeBMC Immunol.62005210.1186/1471-2172-6-215655079 26FaureE.PoissyJ.GoffardA.FournierC.KipnisE.TitecatM.BortolottiP.MartinezL.DubucquoiS.DesseinR.GossetP.MathieuD.GueryB.Distinct immune response in two MERS-CoV-infected"/>
 <result pre="profile of immune response genes in patients with severe acute" exact="respiratory" post="syndromeBMC Immunol.62005210.1186/1471-2172-6-215655079 26FaureE.PoissyJ.GoffardA.FournierC.KipnisE.TitecatM.BortolottiP.MartinezL.DubucquoiS.DesseinR.GossetP.MathieuD.GueryB.Distinct immune response in two MERS-CoV-infected patients:"/>
 <result pre="patients: Can we go from bench to bedside?PLoS One9201410.1371/journal.pone.0088716e88716 27HadjadjJ.YatimN.BarnabeiL.CorneauA.BoussierJ.PereH.CharbitB.BondetV.Chenevier-GobeauxC.BreillatP.CarlierN.GauzitR.MorbieuC.PeneF.MarinN.RocheN.SzwebelT.-A.SmithN.MerklingS.TreluyerJ.-M.VeyerD.MouthonL.BlancC.TharauxP.-L.RozenbergF.FischerA.DuffyD.Rieux-LaucatF.KerneisS.TerrierB.Impaired" exact="type I" post="interferon activity and exacerbated inflammatory responses in severe Covid-19"/>
 <result pre="Clin. Immunol.0202010.1016/j.jaci.2020.04.029 29YoshikawaT.HillT.E.YoshikawaN.PopovV.L.GalindoC.L.GarnerH.R.PetersC.J.Te TsengC.Dynamic innate immune responses of human bronchial" exact="epithelial" post="cells to severe acute respiratory syndrome-associated coronavirus infectionPLoS One5201010.1371/journal.pone.0008729"/>
 <result pre="innate immune responses of human bronchial epithelial cells to severe" exact="acute" post="respiratory syndrome-associated coronavirus infectionPLoS One5201010.1371/journal.pone.0008729 30MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and Restoration of"/>
 <result pre="immune responses of human bronchial epithelial cells to severe acute" exact="respiratory" post="syndrome-associated coronavirus infectionPLoS One5201010.1371/journal.pone.0008729 30MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and Restoration of Severe"/>
 <result pre="acute respiratory syndrome-associated coronavirus infectionPLoS One5201010.1371/journal.pone.0008729 30MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and Restoration of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus Mutant Lacking 2â€™-O-Methyltransferase ActivityJ. Virol.8820144251426410.1128/jvi.03571-1324478444"/>
 <result pre="respiratory syndrome-associated coronavirus infectionPLoS One5201010.1371/journal.pone.0008729 30MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and Restoration of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus Mutant Lacking 2â€™-O-Methyltransferase ActivityJ. Virol.8820144251426410.1128/jvi.03571-1324478444 31ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated"/>
 <result pre="syndrome-associated coronavirus infectionPLoS One5201010.1371/journal.pone.0008729 30MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and Restoration of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus Mutant Lacking 2â€™-O-Methyltransferase ActivityJ. Virol.8820144251426410.1128/jvi.03571-1324478444 31ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated type"/>
 <result pre="coronavirus infectionPLoS One5201010.1371/journal.pone.0008729 30MenacheryV.D.YountB.L.JossetL.GralinskiL.E.ScobeyT.AgnihothramS.KatzeM.G.BaricR.S.Attenuation and Restoration of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus Mutant Lacking 2â€™-O-Methyltransferase ActivityJ. Virol.8820144251426410.1128/jvi.03571-1324478444 31ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated type I"/>
 <result pre="Acute Respiratory Syndrome Coronavirus Mutant Lacking 2â€™-O-Methyltransferase ActivityJ. Virol.8820144251426410.1128/jvi.03571-1324478444 31ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated" exact="type I" post="interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in"/>
 <result pre="31ChannappanavarR.FehrA.R.VijayR.MackM.ZhaoJ.MeyerholzD.K.PerlmanS.Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal" exact="pneumonia" post="in SARS-CoV-Infected miceCell Host Microbe19201618119310.1016/j.chom.2016.01.00726867177 32ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.MeyerholzD.K.PerlmanS.IFN-I response timing relative"/>
 <result pre="32ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.MeyerholzD.K.PerlmanS.IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ. Clin. Invest.12920193625363910.1172/JCI12636331355779 33Blanco-MeloD.Nilsson-PayantB.E.LiuW.C.UhlS.HoaglandD.MÃ¸llerR.JordanT.X.OishiK.PanisM.SachsD.WangT.T.SchwartzR.E.LimJ.K.AlbrechtR.A.B.R. tenOever, imbalanced host response to"/>
 <result pre="Immunol.8201730410.3389/fimmu.2017.0030428408907 36Le BonA.EtchartN.RossmannC.AshtonM.HouS.GewertD.BorrowP.ToughD.F.Cross-priming of CD8+ T cells stimulated by virus-induced" exact="type I" post="interferonNat. Immunol.420031009101510.1038/ni97814502286 37ToughD.F.BorrowP.SprentJ.Induction of bystander T cell proliferation by"/>
 <result pre="Immunol.420031009101510.1038/ni97814502286 37ToughD.F.BorrowP.SprentJ.Induction of bystander T cell proliferation by viruses and" exact="type I" post="interferon in vivoScience (80-.)27219961947195010.1126/science.272.5270.1947 38McNabF.Mayer-BarberK.SherA.WackA.Oâ€™GarraA.Type I interferons in infectious"/>
 <result pre="type I interferon in vivoScience (80-.)27219961947195010.1126/science.272.5270.1947 38McNabF.Mayer-BarberK.SherA.WackA.Oâ€™GarraA.Type I interferons in" exact="infectious" post="diseaseNature Publishing Group201510.1038/nri3787 39Le BonA.SchiavoniG.Dâ€™AgostinoG.GresserI.BelardelliF.ToughD.F.Type i interferons potently enhance"/>
 <result pre="with wt MHV-68Vaccine.2920113935394410.1016/j.vaccine.2011.03.09221481326 44Miquilena-ColinaM.E.Lozano-RodrÃ­guezT.GarcÃ­a-PozoL.SÃ¡ezA.RizzaP.CaponeI.RapicettaM.ChionneP.CapobianchiM.SelleriM.CastillettiC.BelardelliF.Lo IaconoO.GarcÃ­a-MonzÃ³nC.Recombinant interferon-alpha2b improves immune response to" exact="hepatitis" post="B vaccination in haemodialysis patients: results of a randomised"/>
 <result pre="patients: results of a randomised clinical trialVaccine.2720095654566010.1016/j.vaccine.2009.07.01419635606 45AntonelliG.ScagnolariC.MoschellaF.ProiettiE.Twenty-five years of" exact="type I" post="interferon-based treatment: a critical analysis of its therapeutic useCytokine"/>
 <result pre="HarbiS.KojanS.Al JeraisyM.DeebA.M.MemishZ.A.GhazalS.Al FarajS.Al-HameedF.AlSaediA.MandourahY.Al MekhlafiG.A.SherbeeniN.M.ElzeinF.E.AlmotairiA.Al BshabsheA.KharabaA.JoseJ.Al HarthyA.Al SulaimanM.MadyA.FowlerR.A.HaydenF.G.Al-DawoodA.AbdelzaherM.BajhmomW.HusseinM.A.Treatment of Middle East" exact="respiratory" post="syndrome with a combination of lopinavir/ritonavir and interferon-Î²1b (MIRACLE"/>
 <result pre="JeraisyM.DeebA.M.MemishZ.A.GhazalS.Al FarajS.Al-HameedF.AlSaediA.MandourahY.Al MekhlafiG.A.SherbeeniN.M.ElzeinF.E.AlmotairiA.Al BshabsheA.KharabaA.JoseJ.Al HarthyA.Al SulaimanM.MadyA.FowlerR.A.HaydenF.G.Al-DawoodA.AbdelzaherM.BajhmomW.HusseinM.A.Treatment of Middle East respiratory" exact="syndrome" post="with a combination of lopinavir/ritonavir and interferon-Î²1b (MIRACLE trial):"/>
 <result pre="controlled trialTrials.212020810.1186/s13063-019-3846-x31900204 50OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221"/>
 <result pre="trialTrials.212020810.1186/s13063-019-3846-x31900204 50OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221 51ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug"/>
 <result pre="I interferons as regulators of lung inflammationFront. Immunol.8201725910.3389/fimmu.2017.0025928344581 54MeriganT.C.HallT.S.ReedS.E.TyrrellD.A.J.J.UnitM.R.C.C.C.HospitalH.Inhibition of" exact="respiratory" post="virus infection by locally applied InterferonLancet.301197356356710.1016/S0140-6736(73)90714-9 55VelkovT.Abdul RahimN.ZhouQ.T.ChanH.K.LiJ.Inhaled anti-infective"/>
 <result pre="interferons as regulators of lung inflammationFront. Immunol.8201725910.3389/fimmu.2017.0025928344581 54MeriganT.C.HallT.S.ReedS.E.TyrrellD.A.J.J.UnitM.R.C.C.C.HospitalH.Inhibition of respiratory" exact="virus infection" post="by locally applied InterferonLancet.301197356356710.1016/S0140-6736(73)90714-9 55VelkovT.Abdul RahimN.ZhouQ.T.ChanH.K.LiJ.Inhaled anti-infective chemotherapy for"/>
 <result pre="as regulators of lung inflammationFront. Immunol.8201725910.3389/fimmu.2017.0025928344581 54MeriganT.C.HallT.S.ReedS.E.TyrrellD.A.J.J.UnitM.R.C.C.C.HospitalH.Inhibition of respiratory virus" exact="infection" post="by locally applied InterferonLancet.301197356356710.1016/S0140-6736(73)90714-9 55VelkovT.Abdul RahimN.ZhouQ.T.ChanH.K.LiJ.Inhaled anti-infective chemotherapy for"/>
 <result pre="infection by locally applied InterferonLancet.301197356356710.1016/S0140-6736(73)90714-9 55VelkovT.Abdul RahimN.ZhouQ.T.ChanH.K.LiJ.Inhaled anti-infective chemotherapy for" exact="respiratory" post="tract infections: successes, challenges and the road aheadAdv. Drug"/>
 <result pre="following intranasal administrationNeuroscience.152200878579710.1016/j.neuroscience.2008.01.01318304744 59BennettA.L.SmithD.W.CumminsM.J.JacobyP.A.CumminsJ.M.BeilharzM.W.Low-dose oral interferon alpha as prophylaxis against" exact="viral" post="respiratory illness: a double-blind, parallel controlled trial during an"/>
 <result pre="intranasal administrationNeuroscience.152200878579710.1016/j.neuroscience.2008.01.01318304744 59BennettA.L.SmithD.W.CumminsM.J.JacobyP.A.CumminsJ.M.BeilharzM.W.Low-dose oral interferon alpha as prophylaxis against viral" exact="respiratory" post="illness: a double-blind, parallel controlled trial during an influenza"/>
 <result pre="pandemic year, Influenza Other RespiViruses.7201385486210.1111/irv.12094 60BocciV.Absorption of Cytokines via Oropharyngeal-Associated" exact="Lymphoid" post="Tissues: Does an Unorthodox Route Improve the Therapeutic Index"/>
 <result pre="of recombinant human interferon alpha nasal drops to prevent coronavirus" exact="disease" post="2019 in medical staff in an epidemic areaMedRxiv.202010.1101/2020.04.11.200614732020.04.11.20061473 62SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN.Type"/>
 <result pre="against COVID-19Antiviral Res.178202010479110.1016/j.antiviral.2020.10479132275914 63RossT.M.MartinezP.M.RennerJ.C.ThorneR.G.HansonL.R.FreyW.H.Intranasal administration of interferon beta bypasses the" exact="blood-brain barrier" post="to target the central nervous system and cervical lymph"/>
 <result pre="of interferon beta bypasses the blood-brain barrier to target the" exact="central nervous system" post="and cervical lymph nodes: a non-invasive treatment strategy for"/>
 <result pre="she carries out her research activity in the field of" exact="cancer" post="immunology and immunotherapy, in both animal models and clinical"/>
 <result pre="animal models and clinical studies, with a particular focus on" exact="type I" post="Interferons. She worked as visiting fellow at the University"/>
 <result pre="Scotland, UK, in the context of an European Grant on" exact="type I" post="IFN as immune adjuvant (2000). She also spent two"/>
 <result pre="the development and clinical application of cell-based immunotherapy strategies for" exact="cancer" post="and regenerative diseases. Laura Bracci is Researcher at the"/>
 <result pre="aimed at disclosing the mechanisms underlying the immunoadjuvant activities of" exact="systemic" post="and mucosal type I Interferons in both influenza infection"/>
 <result pre="the mechanisms underlying the immunoadjuvant activities of systemic and mucosal" exact="type I" post="Interferons in both influenza infection as well as tumor"/>
 <result pre="of systemic and mucosal type I Interferons in both influenza" exact="infection" post="as well as tumor models. The research activity is"/>
 <result pre="type I Interferons in both influenza infection as well as" exact="tumor" post="models. The research activity is documented by thirty-six publications"/>
 <result pre="peer-reviewed journals (H-index: 21) in the fields of interferon research," exact="infectious diseases," post="oncology and immunology. Luciano Castiello obtained his PhD in"/>
 <result pre="antitumor response. An important achievement was breaking the dogma that" exact="type II" post="IFN expression was a prerogative of lymphoid cells by"/>
 <result pre="recent work focused on the relationship among diet, inflammation and" exact="cancer" post="(Donninelli et al., Frontiers Immunol. 2017; Del CornÃ² et"/>
 <result pre="well as in several prestigious laboratories, including the Laboratory of" exact="Viral" post="Oncology of the â€œInstitut de Recherches Scientifiques sur le"/>
 <result pre="(H-index: 59) regarding the fields of interferon and cytokine research," exact="infectious diseases," post="oncology and immunology. In 2017, he became Senior Research"/>
</results>
